SG131030A1 - New association between agomelatine and a noradrenaline reuptake inhibitor, and pharmaceutical compositions containing it - Google Patents

New association between agomelatine and a noradrenaline reuptake inhibitor, and pharmaceutical compositions containing it

Info

Publication number
SG131030A1
SG131030A1 SG200605974-5A SG2006059745A SG131030A1 SG 131030 A1 SG131030 A1 SG 131030A1 SG 2006059745 A SG2006059745 A SG 2006059745A SG 131030 A1 SG131030 A1 SG 131030A1
Authority
SG
Singapore
Prior art keywords
agomelatine
reuptake inhibitor
pharmaceutical compositions
compositions containing
noradrenaline reuptake
Prior art date
Application number
SG200605974-5A
Other languages
English (en)
Inventor
Elisabeth Mocaer
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of SG131030A1 publication Critical patent/SG131030A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG200605974-5A 2005-09-09 2006-08-31 New association between agomelatine and a noradrenaline reuptake inhibitor, and pharmaceutical compositions containing it SG131030A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0509206A FR2890564B1 (fr) 2005-09-09 2005-09-09 Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
SG131030A1 true SG131030A1 (en) 2007-04-26

Family

ID=36190808

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200605974-5A SG131030A1 (en) 2005-09-09 2006-08-31 New association between agomelatine and a noradrenaline reuptake inhibitor, and pharmaceutical compositions containing it

Country Status (39)

Country Link
US (1) US7622505B2 (ar)
EP (1) EP1769798B1 (ar)
JP (2) JP5395998B2 (ar)
KR (1) KR100863384B1 (ar)
CN (1) CN1927205A (ar)
AP (1) AP2615A (ar)
AR (1) AR056056A1 (ar)
AT (1) ATE404205T1 (ar)
AU (1) AU2006209368B2 (ar)
BR (1) BRPI0603759A (ar)
CA (1) CA2558782C (ar)
CY (1) CY1108319T1 (ar)
DE (1) DE602006002210D1 (ar)
DK (1) DK1769798T3 (ar)
EA (1) EA011650B1 (ar)
ES (1) ES2313590T3 (ar)
FR (1) FR2890564B1 (ar)
GE (1) GEP20094742B (ar)
GT (1) GT200600408A (ar)
HR (1) HRP20080535T3 (ar)
JO (1) JO2521B1 (ar)
MA (1) MA28505B1 (ar)
ME (2) ME02767B (ar)
MX (1) MXPA06010157A (ar)
MY (1) MY142260A (ar)
NO (1) NO338029B1 (ar)
NZ (1) NZ549725A (ar)
PE (1) PE20070429A1 (ar)
PL (1) PL1769798T3 (ar)
PT (1) PT1769798E (ar)
RS (1) RS50631B (ar)
SA (1) SA06270308B1 (ar)
SG (1) SG131030A1 (ar)
SI (1) SI1769798T1 (ar)
TW (1) TWI324513B (ar)
UA (1) UA83542C2 (ar)
UY (1) UY29778A1 (ar)
WO (1) WO2007028904A1 (ar)
ZA (1) ZA200607562B (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608737B2 (en) 2007-05-01 2009-10-27 Concert Pharmaceuticasl Inc. Naphthyl(ethyl)acetamides
US20080280991A1 (en) * 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted naphthalenes
CN102342924A (zh) * 2010-08-05 2012-02-08 北京本草天源药物研究院 一种含有阿戈美拉汀的药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4843071A (en) * 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ZA985765B (en) * 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
EP0919234A3 (en) * 1997-10-17 1999-08-25 Eli Lilly And Company Potentiation of pharmaceuticals by moxonidine
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
AU2003213242A1 (en) * 2002-02-26 2003-09-09 Ortho-Mcneil Pharmaceutical Inc. Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents
JP2004292445A (ja) * 2003-03-11 2004-10-21 Katsunori Nonogaki 糖尿病治療薬
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
JP2007505095A (ja) * 2003-09-12 2007-03-08 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー うつ病及び不安障害の治療のためのアルファ−２−デルタリガンド及びｓｓｒｉ及び／又はｓｎｒｉを含む組み合わせ

Also Published As

Publication number Publication date
ME02758B (me) 2010-06-30
AP2008004378A0 (en) 2008-04-30
EP1769798A1 (fr) 2007-04-04
SI1769798T1 (sl) 2008-12-31
ME02767B (me) 2010-06-30
MY142260A (en) 2010-11-15
CA2558782C (fr) 2012-05-15
JP5395998B2 (ja) 2014-01-22
RS50631B (sr) 2010-06-30
MXPA06010157A (es) 2007-03-08
WO2007028904A1 (fr) 2007-03-15
PE20070429A1 (es) 2007-06-02
MA28505B1 (fr) 2007-04-03
AR056056A1 (es) 2007-09-12
JO2521B1 (ar) 2010-03-17
TWI324513B (en) 2010-05-11
KR20070029606A (ko) 2007-03-14
DE602006002210D1 (de) 2008-09-25
US7622505B2 (en) 2009-11-24
NO20064048L (no) 2007-03-12
NZ549725A (en) 2008-03-28
TW200744570A (en) 2007-12-16
AP2615A (en) 2013-03-14
AU2006209368B2 (en) 2012-07-19
EA011650B1 (ru) 2009-04-28
GEP20094742B (en) 2009-07-27
ZA200607562B (en) 2008-05-28
US20070060654A1 (en) 2007-03-15
DK1769798T3 (da) 2008-11-24
BRPI0603759A (pt) 2007-05-15
FR2890564B1 (fr) 2007-10-19
CN1927205A (zh) 2007-03-14
PL1769798T3 (pl) 2008-12-31
UY29778A1 (es) 2006-10-31
CY1108319T1 (el) 2014-02-12
GT200600408A (es) 2007-05-21
NO338029B1 (no) 2016-07-25
FR2890564A1 (fr) 2007-03-16
UA83542C2 (uk) 2008-07-25
ATE404205T1 (de) 2008-08-15
EP1769798B1 (fr) 2008-08-13
KR100863384B1 (ko) 2008-10-13
EA200601410A1 (ru) 2007-04-27
CA2558782A1 (fr) 2007-03-09
HRP20080535T3 (en) 2008-12-31
JP2011088919A (ja) 2011-05-06
ES2313590T3 (es) 2009-03-01
AU2006209368A1 (en) 2007-03-29
JP2007077147A (ja) 2007-03-29
SA06270308B1 (ar) 2011-10-08
PT1769798E (pt) 2008-09-18

Similar Documents

Publication Publication Date Title
IL196462A (en) (s) - n - (3 - chloro - 4 - cyanophenyl) - 3 - (4 - cyanophenoxy) - 2 - hydroxy - 2 - methylpropanamide, composition and use
IL172965A0 (en) The combination of a serotonin reuptake inhibitors and agomelatine
EA200601449A1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения нарушений сна у пациента с депрессией
JO3440B1 (ar) استخدام الأغوميلاتين في تحضير علاجات لمداولة اضطرابات القلق العام.
IL209789A0 (en) Metabolites of 3-(2-dimethylaminomethyl-cyclohexyl)- phenol, pharmaceutical compositions comprising the same and uses thereof
ZA200801987B (en) N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
SG131030A1 (en) New association between agomelatine and a noradrenaline reuptake inhibitor, and pharmaceutical compositions containing it
IL191992A0 (en) Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
TW200716083A (en) Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders
MY145139A (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
SG131029A1 (en) New association between agomelatine and a thymoregulatory agent and pharmaceutical compositions containing it
JO2631B1 (ar) استخدام الاغوميلاتين للحصول على ادوية لعلاج تلين المادة البيضاء حول بطينات الدماغ
TW200738634A (en) New salt
TW200744571A (en) Combination of β3 receptor agonist and of monoamine reuptake inhibitors, pharmaceutical composition containing it and therapeutic use thereof